Market Exclusive

Aldeyra Therapeutics Inc (NASDAQ:ALDX) price target set to $23.00 by Cantor Fitzgerald

Analyst Ratings For Aldeyra Therapeutics Inc (NASDAQ:ALDX)

Today, Cantor Fitzgerald set its price target on Aldeyra Therapeutics Inc (NASDAQ:ALDX) to $23.00 per share.

There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Aldeyra Therapeutics Inc (NASDAQ:ALDX) is Buy with a consensus target price of $19.25 per share, a potential 153.29% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Aldeyra Therapeutics Inc (NASDAQ:ALDX)
Aldeyra Therapeutics Inc (NASDAQ:ALDX) has insider ownership of 16.99% and institutional ownership of 57.83%.

About Aldeyra Therapeutics Inc (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Aldeyra Therapeutics, Inc. has a collaborative research agreement with Janssen Research & Development, LLC for the development of novel immune-modulating drugs for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Recent Trading Activity for Aldeyra Therapeutics Inc (NASDAQ:ALDX)
Shares of Aldeyra Therapeutics Inc closed the previous trading session at 7.60 −0.050 0.65% with 7.75 shares trading hands.

Exit mobile version